GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (STU:S2P) » Definitions » Interest Income

Simcere Pharmaceutical Group (STU:S2P) Interest Income : €5.1 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Simcere Pharmaceutical Group Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Simcere Pharmaceutical Group's interest income for the six months ended in Dec. 2024 was €1.8 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2024 was €5.1 Mil.

Simcere Pharmaceutical Group Interest Income Historical Data

The historical data trend for Simcere Pharmaceutical Group's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Interest Income Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Income
Get a 7-Day Free Trial 3.30 9.49 8.11 7.06 5.15

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.01 3.99 3.09 3.25 1.81

Simcere Pharmaceutical Group Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €5.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simcere Pharmaceutical Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (STU:S2P) » Definitions » Interest Income
Comparable Companies
HKSE:00512 HKSE:00867 HKSE:03933 HKSE:03320 HKSE:06185 HKSE:01558 HKSE:00570 HKSE:02005 HKSE:01681 HKSE:02186 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
02096:Hong Kong
Address
No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042
Website
https://www.simcere.com
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases, and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Simcere Pharmaceutical Group Headlines

No Headlines